Cytek Biosciences Inc Strategic Asset Allocation Index
Cytek Biosciences Inc strategic asset allocation index. Cytek Biosciences Inc (CTKB) has a Strategic Asset Allocation Index of 3.7% as of June 2023. Strategic assets (PP&E of $15.59 Million plus long-term investments of $-) total $15.59 Million, measured against net assets of $424.18 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See debt-free asset ratio of Cytek Biosciences Inc to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of Cytek Biosciences Inc (2021–2022)
Strategic asset allocation index of Cytek Biosciences Inc from 2021 to 2022. This chart shows how Cytek Biosciences Inc's Strategic Asset Allocation Index has evolved across 2 annual periods from 2021 to 2022. As of June 2023, the index stands at 3.7%, representing strategic assets of $15.59 Million against net assets of $424.18 Million USD. Check CTKB tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Cytek Biosciences Inc Strategic Asset Allocation Index by Year (2021–2022)
Cytek Biosciences Inc strategic asset allocation index by year from 2021 to 2022. The table below presents the year-by-year Strategic Asset Allocation Index for Cytek Biosciences Inc from 2021 to 2022, covering 2 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see market cap of Cytek Biosciences Inc.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 3.2% | $13.68 Million | $13.68 Million | $- | $425.55 Million | ▲ +1.8 pp |
| 2021 | 1.4% | $5.85 Million | $5.85 Million | $- | $405.38 Million | — |